Organization
Talaris Therapeutics
7 clinical trials
Clinical trial
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx InfusionStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 DonorsStatus: Terminated, Estimated PCD: 2023-02-16
Clinical trial
Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesStatus: Withdrawn, Estimated PCD: 2016-05-01
Clinical trial
Allogeneic Stem Cell Transplantation for the Treatment of Multiple SclerosisStatus: Withdrawn, Estimated PCD: 2024-12-01
Clinical trial
A Single-arm, Multi-center, Exploratory Safety and Efficacy Study of FCR001 Cell-based Therapy to Induce Donor-specific Tolerance in Previously Transplanted Recipients of a Kidney From a Living Donor, and Safety in FCR001 DonorsStatus: Withdrawn, Estimated PCD: 2023-02-28
Clinical trial
A Single-arm, Multi-center, Open-label Proof of Concept Safety and Efficacy Study of FCR001 Cell-based Therapy in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis at Risk for Organ FailureStatus: Withdrawn, Estimated PCD: 2026-11-01
Clinical trial
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersStatus: Terminated, Estimated PCD: 2016-04-01